Table 4.
Summary of Dutasteride Versus Finasteride
| Dutasteride (0.5 mg) | Finasteride (5 mg) | |
|---|---|---|
| 5AR inhibition | Type 1 and 2 | Type 2 only |
| % DHT inhibition (serum) | 93% | 70% |
| Half-life | 5 weeks | 6 to 8 hours |
| Prostate size reduction | −25.7% (2 y) | −18% (4 y, PLESS) |
| (from baseline) | −27.3% (4 y) | −16% (4.5 y, MTOPS) |
| Urinary flow | 2.2 mL/sec (2 y) | 1.7 mL/sec (4 y, PLESS) |
| improvement (Qmax) | 2.7 mL/sec (4 y) | 2.2 mL/sec (4.5 y, MTOPS) |
| Improvement in symptoms | −4.4 (2 y) | −3.3 (4 y, PLESS) |
| (AUA-SI) | −6.5 (4 y) | −5.0 (4.5 y, MTOPS) |
| % Reduction in AUR | 57% (2 y) | 57% (4 y, PLESS) |
| 79% (4.5 y, MTOPS) | ||
| % Reduction in surgery | 48% (2 y) | 55% (4 y, PLESS) |
| 69% (4.5 y, MTOPS) |
5AR, 5α-reductase; DHT, dihydrotestosterone; PLESS, Proscar Long-Term Efficacy and Safety Study; MTOPS, Medical Treatment of Prostate Symptoms Study; Qmax, maximum flow rate; AUA-SI, American Urological Association-Symptom Index; AUR, acute urinary retention.